168 related articles for article (PubMed ID: 34994942)
1. BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.
Abdelrazek MA; Nageb A; Barakat LA; Abouzid A; Elbaz R
Breast Cancer; 2022 May; 29(3):507-515. PubMed ID: 34994942
[TBL] [Abstract][Full Text] [Related]
2. Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors.
Sai Baba KSS; Rehman MA; Pradeep Kumar J; Fatima M; Raju GSN; Uppin SG; Mohammed N
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2509-2507. PubMed ID: 34452565
[TBL] [Abstract][Full Text] [Related]
3. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
4. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
[TBL] [Abstract][Full Text] [Related]
5. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
7. Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer.
Lu M; Ju S; Shen X; Wang X; Jing R; Yang C; Chu H; Cong H
Cancer Biomark; 2017; 18(2):143-148. PubMed ID: 27983524
[TBL] [Abstract][Full Text] [Related]
8. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
[TBL] [Abstract][Full Text] [Related]
9. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
[TBL] [Abstract][Full Text] [Related]
10. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
11. Human epididymal protein 4 and its combined detection show good diagnostic value in lung cancer: A retrospective study.
Wu L; Chen X; Peng T; Tang E; Bai W; Chen L
Int J Biol Markers; 2024 Jun; 39(2):141-148. PubMed ID: 38619974
[TBL] [Abstract][Full Text] [Related]
12. Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.
Ning L; Lang J; Wu L
BMC Cancer; 2022 Jan; 22(1):6. PubMed ID: 34980005
[TBL] [Abstract][Full Text] [Related]
13. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
15. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of HE4 and ROMA among Chinese women.
Shen Y; Zhao L; Lu S
Clin Chim Acta; 2020 Jan; 500():42-46. PubMed ID: 31626761
[TBL] [Abstract][Full Text] [Related]
18. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
19. A strengthening the reporting of observational studies in epidemiology (STROBE): Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?
Dellino M; Gargano G; Tinelli R; Carriero C; Minoia C; Tetania S; Silvestris E; Loizzi V; Paradiso A; Casamassima P; Tufaro A; Cormio G; Garrisi VM
Medicine (Baltimore); 2021 Feb; 100(5):e24485. PubMed ID: 33592901
[TBL] [Abstract][Full Text] [Related]
20. Serum HE4 as a diagnostic and prognostic marker for lung cancer.
Iwahori K; Suzuki H; Kishi Y; Fujii Y; Uehara R; Okamoto N; Kobayashi M; Hirashima T; Kawase I; Naka T
Tumour Biol; 2012 Aug; 33(4):1141-9. PubMed ID: 22373583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]